AI-enhanced breast MRI with a 75% reduced gadolinium dose maintained diagnostic sensitivity comparable to full-dose protocols.
Key Details
- 1Single-center study with 20 female participants having biopsy-proven malignancies or high-risk indications.
- 2Low-dose (0.025 mmol/kg) MRI scans with AI were compared to standard-dose (0.1 mmol/kg) with/without AI.
- 3Diagnostic sensitivity with low-dose + AI was 83.3% (p=1 vs. standard), accuracy was 74.5% vs. 69.5% (standard) and 65.5% (standard+AI).
- 498 lesions detected; 12 were biopsy-proven malignancies; high NPVs (93-94%) across all protocols.
- 5AI-assisted low-dose MRI had the highest PPV (50%) and substantial interreader agreement (kappa 0.65-0.74).
- 6Study was small and lacked long-term outcome data; funded by Bracco.
Why It Matters
Gadolinium retention and cost are growing concerns in breast imaging. This study shows that AI-powered image enhancement could allow safer, lower-dose protocols without compromising cancer detection, marking a significant step for both patient safety and clinical feasibility.
Source
AuntMinnie
Related News
•Radiology Business
New AI Flags Uncertainty in Breast Cancer Imaging Predictions
University of Pittsburgh researchers developed an AI model that quantifies uncertainty in breast cancer diagnostic predictions to enhance trustworthiness.
•Radiology Business
FDA Approves SimBioSys AI Tool for Breast Cancer Risk via MRI
SimBioSys received FDA clearance for TumorSight Risk, an AI tool assessing breast cancer recurrence risk using MRI.
•AuntMinnie
LLMs Rarely Recommend Unnecessary Imaging, Except for Thyroid Ultrasound
Large language models seldom over-recommend imaging, but thyroid ultrasound guidance shows substantial discrepancies.